Computational evidence
| Protein change | ||
| AlphaMissense | 0.1683 | likely benign |
|---|---|---|
| REVEL | 0.289 | benign-leaning |
| SaProt | LLR -9.22 | tolerated |
| ⇒ AlphaMissense, REVEL and SaProt all call this tolerated. | ||
| Splicing | ||
| SpliceAI | <0.2 | all four deltas below 0.2 · C>A here scores Δ0.82 · evaluated, not missing |
| Constraint at this position | ||
| Conservation | phyloP 1 | GERP -1.3, phastCons 0.27 |
| Regional constraint | o/e 0.91 | unconstrained · MANE · 14 kb · p 0.038 · regional, not allelic |
| Overall | ||
| CADD | 22.1 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| Finnishnot grpmax-eligible | 6.3% | 16 |
| European (non-Finnish)grpmax | 4.82% | 21 |
| Remaining individualsnot grpmax-eligible | 3.78% | 26 |
| Amishnot grpmax-eligible | 3.73% | 27 |
| Ashkenazi Jewishnot grpmax-eligible | 2.41% | 41 |
| Admixed American | 2.17% | 46 |
| Middle Eastern | 1.37% | 73 |
| African / African-American | 0.877% | 114 |
| South Asian | 0.688% | 145 |
| East Asian | 0.00223% | 44,868 |
Finnish shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- ACADS
- Protein
- p.Arg171Trp
- Coding
- c.511C>T
- MANE Select
- NM_000017
- dbSNP
- rs1800556
- Type
- single nucleotide variant
- Location
- chr12:120737875 (GRCh38)
- Gene constraint
- LOEUF 0.852 · pLI <0.01 (gnomAD)
- Structure
- AlphaFold pLDDT 93.58 · 4 PDB
- Residue 171
- a UniProt-annotated variant site (69% of wild-type acyl-coa dehydrogenase activity; confers susceptibility to ethylmalonicaciduria); a β-strand
Disease context
short chain acyl-CoA dehydrogenase deficiency — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsFor Short chain acyl-CoA dehydrogenase deficiency (Orphanet):
- Inheritance
- Autosomal recessive
- Onset
- Childhood, Infancy, Neonatal
Similar variants
- ACADS c.211-2A>G Likely pathogenic ★★ same condition
- ACADS c.625-1G>A Likely pathogenic ★★ same condition
- ACADS c.795+1G>A Pathogenic/Likely pathogenic ★★ same condition
- ACADS p.Ala199Val Likely pathogenic ★★ ⚠ same condition
- ACADS p.Arg107Cys Pathogenic ★★ ⚠ same condition
- ACADS p.Arg272Cys Pathogenic/Likely pathogenic ★★ same condition
- ACADS p.Arg325Gln Pathogenic/Likely pathogenic ★★ ⚠ same condition
- ACADS p.Arg325Trp Pathogenic/Likely pathogenic ★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/acads-p-arg171trp (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown